Evodiamine Improves Congnitive Abilities in SAMP8 and APP(swe)/PS1(ΔE9) Transgenic Mouse Models of Alzheimer's Disease

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2011 Feb 1

PMID 21278785

Citations 25

Authors

Shu-Min Yuan

Kai Gao

Dong-Mei Wang

Xiong-Zhi Quan

Jiang-Ning Liu

Chun-Mei Ma

Chuan Qin

Lian-Feng Zhang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models.

Methods: The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg(-1)·d(-1) and 100 mg·kg(-1)·d(-1)) groups and an Aricept (2 mg·kg(-1)·d(-1)) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris water-maze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot.

Results: In Morris water-maze test, evodiamine (100 mg·kg(-1)·d(-1)) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg(-1)·d(-1)) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease.

Conclusion: The results indicate that evodiamine (100 mg·kg(-1)·d(-1)) improves cognitive abilities in the transgenic models of Alzheimer's disease.

Citing Articles

Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from .

Lin L, Liu Y, Tang R, Ding S, Lin H, Li H Int J Nanomedicine. 2024; 19:9843-9870.

PMID: 39345907 PMC: 11430234. DOI: 10.2147/IJN.S459510.

Effects of Evodiamine on Behavior and Hippocampal Neurons through Inhibition of Angiotensin-Converting Enzyme and Modulation of the Renin Angiotensin Pathway in a Mouse Model of Post-Traumatic Stress Disorder.

Wang Z, Lai C, Shen B, Li B, Chen J, Shen X Nutrients. 2024; 16(12).

PMID: 38931311 PMC: 11207023. DOI: 10.3390/nu16121957.

Traditional Chinese medicine Euodiae Fructus: botany, traditional use, phytochemistry, pharmacology, toxicity and quality control.

Xiao S, Xu X, Chen W, Xin J, Yuan W, Zu X Nat Prod Bioprospect. 2023; 13(1):6.

PMID: 36790599 PMC: 9931992. DOI: 10.1007/s13659-023-00369-0.

Discovery of an evodiamine derivative for PI3K/AKT/GSK3β pathway activation and AD pathology improvement in mouse models.

Pang S, Li S, Cheng H, Luo Z, Qi X, Guan F Front Mol Neurosci. 2023; 15:1025066.

PMID: 36698780 PMC: 9868638. DOI: 10.3389/fnmol.2022.1025066.

Synthesis and Bioactivity Evaluation of a Novel 1,2,4-Oxadiazole Derivative in vitro and in 3×Tg Mice.

Luo Z, Wang Y, Pang S, Gao S, Liu N, Gao X Drug Des Devel Ther. 2022; 16:3285-3296.

PMID: 36187086 PMC: 9521684. DOI: 10.2147/DDDT.S372750.

References

Yoshizumi M, Houchi H, Ishimura Y, Hirose M, Kitagawa T, Tsuchiya K . Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest. 1997; 44(1-2):79-82. View

Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T . Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol. 2009; 87(3):181-94. DOI: 10.1016/j.pneurobio.2009.01.001. View

Rojo L, Fernandez J, Maccioni A, Jimenez J, Maccioni R . Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2007; 39(1):1-16. DOI: 10.1016/j.arcmed.2007.10.001. View

Yamamoto K, Arakawa T, Ueda N, Yamamoto S . Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem. 1995; 270(52):31315-20. DOI: 10.1074/jbc.270.52.31315. View

Hayden K, Zandi P, Khachaturian A, Szekely C, Fotuhi M, Norton M . Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology. 2007; 69(3):275-82. DOI: 10.1212/01.wnl.0000265223.25679.2a. View

Butterfield D, Poon H . The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol. 2005; 40(10):774-83. DOI: 10.1016/j.exger.2005.05.007. View

Chiou W, Chou C, Shum A, Chen C . The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol. 1992; 215(2-3):277-83. DOI: 10.1016/0014-2999(92)90039-7. View

Kobayashi Y . The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 2003; 69(5):425-8. DOI: 10.1055/s-2003-39701. View

Yu A, Lin H, Huang S, Phelps M, Wu H . Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med. 2009; 50(6):966-73. PMC: 2761751. DOI: 10.2967/jnumed.108.060533. View

10.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

11.

Ko H, Wang Y, Liou K, Chen C, Chen C, Wang W . Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol. 2006; 555(2-3):211-7. DOI: 10.1016/j.ejphar.2006.10.002. View

12.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis N, Rosenmann H . NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis. 2009; 34(2):381-8. DOI: 10.1016/j.nbd.2009.02.011. View

13.

King C, Kong Y, Wong N, Yeung H, Fong H, Sankawa U . Uterotonic effect of Evodia rutaecarpa alkaloids. J Nat Prod. 1980; 43(5):577-82. DOI: 10.1021/np50011a008. View

14.

Cox M, Tucker A, Tang J, Talbot K, Richer D, Yeh L . Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009; 8(4):390-7. PMC: 2774142. DOI: 10.1111/j.1601-183X.2009.00477.x. View

15.

Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X . miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull. 2009; 80(4-5):268-73. DOI: 10.1016/j.brainresbull.2009.08.006. View

16.

Blass J . Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?. J Neurosci Res. 2001; 66(5):851-6. DOI: 10.1002/jnr.10087. View

17.

Jiang J, Hu C . Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules. 2009; 14(5):1852-9. PMC: 6254303. DOI: 10.3390/molecules14051852. View

18.

Vallieres L, Rivest S . Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J Neurochem. 1997; 69(4):1668-83. DOI: 10.1046/j.1471-4159.1997.69041668.x. View

19.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

20.

Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K . Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol. 2004; 165(3):987-95. PMC: 1618604. DOI: 10.1016/s0002-9440(10)63360-3. View